AMORPHOUS FORM OF APREMILAST
    5.
    发明公开

    公开(公告)号:EP3143004A4

    公开(公告)日:2017-11-08

    申请号:EP14892030

    申请日:2014-07-20

    申请人: MAPI PHARMA LTD

    IPC分类号: C07D209/44 A61K31/4035

    摘要: The present invention provides a new amorphous form of apremilast, pharmaceutical compositions comprising same, methods for preparation and use thereof in treating conditions mediated by inhibition of TNF-α production or inhibition of phosphodiesterase 4 (PDE4), e.g., psoriatic arthritis and other chronic inflammatory diseases.

    DEPOT SYSTEM COMPRISING GLATIRAMER ACETATE
    10.
    发明公开

    公开(公告)号:EP3536333A1

    公开(公告)日:2019-09-11

    申请号:EP18205308.2

    申请日:2010-08-19

    申请人: Mapi Pharma Ltd.

    IPC分类号: A61K38/00 A61P25/00

    摘要: The present invention provides long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer. In particular, the present invention provides a long acting pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection.